The weight‑loss drug divide: Private prescribing is lowest where need is greatest

For many people living with obesity, Wegovy and Mounjaro offer the possibility of substantial weight loss without surgery. Yet data from one private provider points to a troubling divide: Prescription rates of these drugs in England are lowest in communities where obesity is most common.

≈